Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

r a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: INVESTOR RELATIONS CONTACTS

Spectranetics Corporation Lippert/Heilshorn & Associates, Inc.

Guy Childs, Chief Financial Officer Bruce Voss/Don Markley

(719) 633-8333 (310) 691-7100

http://www.spectranetics.com http://www.lhai.com

MEDIA RELATIONS CONTACT:

Schwartz Communications, Inc.

Stacey Holifield

(781) 684-0770

spectranetics@schwartz-pr.com


'/>"/>
SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Ariz. , July 28 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... 2011 first quarter ended June 30, 2010 , will be released after ... call will be held the following morning on Wednesday, August 4, 2010 ... , , ...
... Eli Lilly and Company (NYSE: LLY ) today announced that the ... by the U.S. District Court for the Eastern District of Michigan ... , , ... Gemzar,s method-of-use patent. We continue to believe that our Gemzar method-of-use patent should ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) ... study of CDX-1401 in solid tumors, including long-term patient ... (Vol 6 Issue 232). The data demonstrate robust ... benefit in patients with very advanced cancers and suggest ...
(Date:4/16/2014)... treatments are the leading cause of increases in multiple ... premature birth, these results are not inevitable, concludes an ... The article identifies six changes in policy and practice ... prematurity, including expanding insurance coverage for in vitro fertilization ...
(Date:4/15/2014)... CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... to fight invasive fungal infections, which kill about 1.5 million people ... action of amphotericin, an antifungal drug that has been in use ... as toxic to human cells as it is to the microbes ...
(Date:4/14/2014)... in chemotherapy over the past decade, but targeting drugs ... be a major challenge. , Nanotechnology has unlocked ... of nanocarriers, or capsules, that can transport cargoes of ... The catch? These carriers are tiny, and it matters ...
Breaking Medicine News(10 mins):Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2
... Cell-Based ... Melanoma Therapy, BOTHELL, Wash., ... developer and marketer of,proprietary hypothermic storage and cryopreservation media products for,cells, ... products in the cellular therapy and cord blood banking,market segments., ...
... Michelle Reesman, RN, Executive,Director, Passport Health Colorado, says far ... adventurous types, leave,home without taking the basic steps she ... preparation into their health as they do into their,destination ... 1) Get advice from a travel health ...
... LENEXA, Kan., Mar. 26 Mediware Information,Systems (Nasdaq: ... systems for,blood and medication management, has announced its ... hospital,blood banks and LifeTrak(R) software for blood centers, ... standards being required in the,United States., With ...
... for Voters on Health Care and,Social Security, ... said the most recent Medicare trustees, report calls ... issues.,According to the program,s trustees, Medicare,s Hospital Insurance ... Medicare must,rely also on interest accrued on trust ...
... 26 Spheris, a leading global,outsource provider of clinical ... and twelve months ended December 31, 2007., Financial ... fourth quarter of 2007 were $48.6 million compared,with $51.4 ... million decrease,in net revenues during the fourth quarter of ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: